Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $112.25

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $131.83.

Several equities research analysts recently commented on PCVX shares. Jefferies Financial Group raised their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday. Needham & Company LLC raised their target price on Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. Bank of America raised their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Leerink Partners raised their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday.

Insider Buying and Selling

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $81.17, for a total transaction of $649,360.00. Following the sale, the chief financial officer now directly owns 96,720 shares in the company, valued at $7,850,762.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total value of $1,119,300.00. Following the sale, the chief operating officer now directly owns 207,503 shares in the company, valued at $23,225,810.79. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $81.17, for a total value of $649,360.00. Following the completion of the sale, the chief financial officer now owns 96,720 shares in the company, valued at $7,850,762.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,283 shares of company stock worth $7,271,218. 3.10% of the stock is owned by company insiders.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Clearbridge Investments LLC bought a new stake in shares of Vaxcyte during the 2nd quarter valued at $14,056,000. Novo Holdings A S raised its stake in shares of Vaxcyte by 12.4% during the 2nd quarter. Novo Holdings A S now owns 950,000 shares of the company’s stock valued at $71,734,000 after purchasing an additional 105,000 shares during the period. Creative Planning grew its position in Vaxcyte by 64.0% during the second quarter. Creative Planning now owns 27,280 shares of the company’s stock worth $2,060,000 after buying an additional 10,642 shares in the last quarter. Algert Global LLC grew its position in Vaxcyte by 161.1% during the second quarter. Algert Global LLC now owns 34,752 shares of the company’s stock worth $2,624,000 after buying an additional 21,442 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its position in Vaxcyte by 3.6% during the second quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company’s stock worth $146,093,000 after buying an additional 66,940 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Up 2.7 %

Vaxcyte stock opened at $112.10 on Tuesday. The company has a market capitalization of $12.20 billion, a PE ratio of -26.19 and a beta of 0.97. Vaxcyte has a 12 month low of $44.20 and a 12 month high of $119.27. The stock has a 50-day moving average price of $81.08 and a two-hundred day moving average price of $73.28.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). During the same quarter in the previous year, the company posted ($0.70) earnings per share. As a group, analysts predict that Vaxcyte will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.